Pen devices to improve patient adherence with insulin therapy in type 2 diabetes

Postgraduate Medicine

Volumn 120, Issue 3, 2008, Pages 172-179

  Goldstein, Henry Howard ^a,b  

^a Diabetes and Endocrinology Group   (United States)

^b NONE   (United States)

Author keywords

Health economics; Insulin pen devices; Type 2 diabetes mellitus

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ANTIDIABETIC AGENT;

ARTICLE; COMPARATIVE STUDY; COST; DEVICE; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; SYRINGE; INJECTION; INSTRUMENTATION; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; PATIENT COMPLIANCE;

EID: 56149120709     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.09.1917     Document Type: Article

References (33)

1. Wild S, Roglie G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
2. American Diabetes Association. Diabetes Statistics. http.//www.diabetes. org/diabetes-statistics.jsp. Accessed August-29, 2008.
3. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: general information and national estimates on diabetes in the United States, 2005. National Diabetes 2005. Abstract.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. (Pubitemid 28416718)
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.
7. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. (Pubitemid 30609442)
8. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002. The National Health and Nutrition Examination Survey. Diabetes Care. 2006;29(3):531-537.
9. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144(7):465-474.
10. American Association of Clinical Endocrinologists. American College of Endocrinology consensus statement on guidelines for glycemic control. http://www.aace.com/meetings/consensus/dcc/pdf/dccwhitepaper.pdf. Accessed August 29, 2008.
11. State of Diabetes in America™ Report. http.//www.aace.com/public/ awareness/stateofdiabetes/DiabetesAmericaReport.pdf. Accessed August 29, 2008.
12. Skovlund SE, Peyrot M. The Diabetes Attitudes, Wishes, and Needs (DAWN) Program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum. 2005;18(3):136-142. (Pubitemid 41665885)
13. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224. (Pubitemid 38579798)
14. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-1725. (Pubitemid 44841979)
15. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes. 2002;26(suppl 3):S18-S24. (Pubitemid 35034478)
16. Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28(3):600-606. (Pubitemid 40326231)
17. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679. (Pubitemid 43951158)
18. Simincrio L. Challenges and strategies for moving patients to injectable medications. Diabetes Educ. 2006;32(suppl 2):82S-90S.
19. Cryer PE, Childs BP. Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum. 2002;15:20-27.
20. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523-1534. (Pubitemid 44297431)
21. UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22(7):1125-1136. (Pubitemid 29293966)
22. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 2007;77(1):1-15. (Pubitemid 46590471)
23. Kolendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med. 2006;23(7):729-735. (Pubitemid 44366070)
24. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23(8):1130-1136. (Pubitemid 30616801)
25. Pfutzner A, Asakura T, Sommavilla B, et al. Insulin delivery with FlexPen®: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv. 2008;5(8):915-925.
26. Korytkowski M, Bell D, Jacobson C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848. (Pubitemid 37510593)
27. Sucic M, Galic E, Cabrijan T, et al. Patient acceptance and reliability of new Humulin®/Humalog® 3.0 ml prefilled insulin pen in ten Croatian diabetes centres. Med Sci. Monit. 2002;8(3):P121-P126. (Pubitemid 34263058)
28. Niskanen L, Jensen LE, Rástam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26(4):531-540. (Pubitemid 38586454)
29. Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technol Ther. 2005;7(4):620-626. (Pubitemid 41208625)
30. Venekamp WJ, Kerr L, Dowsett SA, et al. Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Curr Med Res Opin. 2006;22(2):315-325. (Pubitemid 44296755)
31. Lawton S, Berg B. Comparative evaluation of FlexPen®, a new prefilled insulin delivery system, among patients and healthcare professionals. Diabetes. 2001;50:A440. Abstract
32. Davis EM, Christensen CM, Nystrom KK, et al. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65(14):1347-1357.
33. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educator. 2002;28(1):52-60.